IAG and Collaborators will present at ESMO 2020

IAG and Collaborators will present at ESMO 2020

IAG, Image Analysis GroupMD Anderson Cancer Center and Soricimed Biopharma will present at the European Society for Medical Oncology (ESMO) virtual congress.

IAG, MD Anderson Cancer Center and Soricimed Biopharma will present ‘Trial in progress: A Phase Ib study on a TRPV6-inhibitor, SOR-C13 in patients with advanced solid tumors’  at European Society for Medical Oncology, ESMO 2020.

The presenter is Dr Siqing Fu, MD Anderson Cancer Center.  The abstarct will be available for delegates to view on demand on the Congress platform starting from 09 am CEST on September 17 until September 21, 8 pm CEST.

The publication is based upon the data collected and in a Phase 1b investigator-initiated trial of late-stage pancreatic cancer. Our research explores the use of advanced image assessment and AI-derived markers to predict patient’s response to Sorc-C13, the first highly specific inhibitor of TRPV6, a calcium channel known to be involved in oncogene expression. This work demonstrates how advanced imaging can be integrated alongside standard radiographic outcome measures into oncology clinical trials and can be used as predictive marker to obtain early efficacy read-outs.  

At ESMO, our team and collaborators will be discussing how advanced image analysis methodologies for assessment of structural and functional tumor changes can accelerate efficacy assessments in oncology programs.


To receive an abstract or to speak to our experts please email: diana.roettger@ia-grp.com

About Image Analysis Group (IAG)

IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner.  IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.

Learn more:  wp1.ia-grp.com

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin